Time filter

Source Type

Kitakyushu, Japan

Seinan Jo Gakuin University is a private women's college in Kitakyushu, Fukuoka, Japan. The predecessor of the school was founded in 1922, and it was chartered as a university in 1994. Wikipedia.

Baba S.-I.,Kyushu University | Tashiro Y.,Seinan Jo Gakuin University | Shinto H.,Kyushu University | Sonomoto K.,Kyushu University
Journal of Biotechnology

Living cells are alive and have the butanol-producing ability but not much proliferation under nitrogen source-limited condition. We investigated various butanol production systems with high density of living cells of Clostridium saccharoperbutylacetonicum N1-4 supplemented with methyl viologen (MV) as an electron carrier and nutrient dosing for activity regeneration. In continuous butanol production with high density of living cells, butanol yield was drastically increased from 0.365C-mol/C-mol with growing cells to 0.528C-mol/C-mol at a dilution rate of 0.85h -1, being increased with the butanol to total solvent ratio. This yield was increased to 0.591C-mol/C-mol by adding 0.01mM MV. MV addition increased not only butanol yield but also butanol concentration and productivity as compared to those without MV addition. However, living cells lost their activity with incubation time, which lowered the operational stability of the system. Therefore, to maintain constant stability, activity regeneration was carried out with high density of living cells and MV. This system produced butanol at high concentration (9.40gl -1) and productivity (7.99gl -1h -1) for approximately 100h with maintenance of considerably high yield of butanol (0.686C-mol/C-mol). Thus, we established a high-speed and highly efficient butanol production system. © 2011 Elsevier B.V. Source

Miyazaki C.,Fukuoka West Rehabilitation Center for Children | Okada K.,Fukuoka Dental College | Ozaki T.,Konan Kosei Hospital | Hirose M.,Hirose Pediatric Clinic | And 5 more authors.
Clinical and Vaccine Immunology

The immunogenicity and safety of an inactivated cell culture Japanese encephalitis vaccine (CC-JEV) were compared with those of an inactivated mouse brain-derived Japanese encephalitis vaccine (MB-JEV) in phase III clinical multicenter trials conducted in children. The vaccines contain the same Japanese encephalitis virus strain, the Beijing-1 strain. Two independent clinical trials (trials 1 and 2) were conducted. Trial 1 was conducted in 468 healthy children. Each subject was injected with 17 μg per dose of either CC-JEV or MB-JEV, and the immunogenicity and safety of the vaccines were investigated. Trial 1 showed that CC-JEV was more immunogenic and reactive than MB-JEV at the same dose. Therefore, to adjust the immunogenicity of CC-JEV to that of MB-JEV, a vaccine that has had a good track record regarding its efficacy for a long time, trial 2 was conducted in 484 healthy children. To improve the stability, CC-JEV was converted from a liquid type to a freeze-dried type of vaccine. Each subject was injected subcutaneously with either 4 μg per dose of CC-JEV, 8 μg per dose of CC-JEV, or 17 μg per dose of MB-JEV twice, at an interval of 2 to 4 weeks, followed by an additional booster immunization 1 to 15 months after the primary immunization. Based on the results of trial 2, 4 μg per dose of the freeze-dried CC-JEV (under the label Encevac) was selected as a substitute for the MB-JEV. Encevac was approved and launched in 2011 and has since been in use as a 2nd-generation Japanese encephalitis vaccine in Japan. (These studies have been registered at the JapicCTI under registration no. JapicCTI-132063 and JapicCTI-080586 for trials 1 and 2, respectively.) Copyright © 2014, American Society for Microbiology. All Rights Reserved. Source

Okada K.,Fukuoka National Hospital | Miyazaki C.,Fukuoka West Rehabilitation Center for Children | Kino Y.,Chemo Sero Therapeutic Research Institute Kaketsuken | Ozaki T.,Konan Kosei Hospital | And 2 more authors.
Journal of Infectious Diseases

Background. Phase II and III clinical studies were conducted to evaluate immunogenicity and safety of a novel DTaP-IPV vaccine consisting of Sabin inactivated poliovirus vaccine (sIPV) and diphtheria-tetanus-acellular pertussis vaccine (DTaP).Methods. A Phase II study was conducted in 104 healthy infants using Formulation H of the DTaP-sIPV vaccine containing high-dose sIPV (3, 100, and 100 D-antigen units for types 1, 2, and 3, respectively), and Formulations M and L, containing half and one-fourth of the sIPV in Formulation H, respectively. Each formulation was administered 3 times for primary immunization and once for booster immunization. A Phase III study was conducted in 342 healthy infants who received either Formulation M + oral polio vaccine (OPV) placebo or DTaP + OPV. The OPV or OPV placebo was orally administered twice between primary and booster immunizations.Results. Formulation M was selected as the optimum dose. In the Phase III study, the seropositive rate was 100% for all Sabin strains after primary immunization, and the neutralizing antibody titer after booster immunization was higher than in the control group (DTaP + OPV). All adverse reactions were clinically acceptable.Conclusions. DTaP-sIPV was shown to be a safe and immunogenic vaccine.Clinical Trials Registration. JapicCTI-121902 for Phase II study, JapicCTI-101075 for Phase III study (http://www.clinicaltrials.jp/user/cte-main.jsp). © 2013 The Author 2013. All rights reserved. Source

Sonomoto K.,Kyushu University | Oshiro M.,Kyushu University | Hanada K.,Kyushu University | Tashiro Y.,Seinan Jo Gakuin University
Applied Microbiology and Biotechnology

In order to achieve high butanol production by Clostridium saccharoperbutylacetonicum N1-4, the effect of lactic acid on acetone-butanol-ethanol fermentation and several fed-batch cultures in which lactic acid is fed have been investigated. When a medium containing 20 g/l glucose was supplemented with 5 g/l of closely racemic lactic acid, both the concentration and yield of butanol increased; however, supplementation with more than 10 g/l lactic acid did not increase the butanol concentration. It was found that when fed a mixture of lactic acid and glucose, the final concentration of butanol produced by a fed-batch culture was greater than that produced by a batch culture. In addition, a pH-controlled fed-batch culture resulted in not only acceleration of lactic acid consumption but also a further increase in butanol production. Finally, we obtained 15.5 g/l butanol at a production rate of 1.76 g/l/h using a fed-batch culture with a pH-stat continuous lactic acid and glucose feeding method. To confirm whether lactic acid was converted to butanol by the N1-4 strain, we performed gas chromatography-mass spectroscopy (GC-MS) analysis of butanol produced by a batch culture during fermentation in a medium containing [1,2,3-13C3] lactic acid as the initial substrate. The results of the GC-MS analysis confirmed the bioconversion of lactic acid to butanol. © Springer-Verlag 2010. Source

Tanaka S.,Saga University | Tanaka S.,Osaka Municipal Technical Research Institute | Tashiro Y.,Seinan Jo Gakuin University | Tashiro Y.,Kyushu University | And 4 more authors.
Bioresource Technology

A polytetrafluoroethylene (PTFE) membrane was used in membrane-assisted extractive (MAE) fermentation of acetone-butanol-ethanol (ABE) by Clostridium saccharoperbutylacetonicum N1-4. The growth inhibition effects of 1-dodecanol, which has a high partition coefficient for butanol, can be prevented by employing 1-dodecanol as an extractant when using a PTFE membrane. Compared to conventional fermentation, MAE-ABE fermentation with 1-dodecanol decreased butanol inhibition and increased glucose consumption from 59.4 to 86.0g/L, and total butanol production increased from 16.0 to 20.1g/L. The maximum butanol production rate increased from 0.817 to 0.979g/L/h. The butanol productivity per membrane area was remarkably high with this system, i.e., 78.6g/L/h/m 2. Therefore, it is expected that this MAE fermentation system can achieve footprint downsizing. © 2012 Elsevier Ltd. Source

Discover hidden collaborations